BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21716161)

  • 1. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
    Gauchotte G; Philippe C; Lacomme S; Léotard B; Wissler MP; Allou L; Toussaint B; Klein M; Vignaud JM; Bressenot A
    Pathology; 2011 Aug; 43(5):447-52. PubMed ID: 21716161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis.
    Kim KH; Suh KS; Kang DW; Kang DY
    Pathol Int; 2005 Sep; 55(9):540-5. PubMed ID: 16143028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of BRAF V600E mutation in different thyroid lesions].
    Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas.
    Lee JH; Lee ES; Kim YS; Won NH; Chae YS
    Pathology; 2006 Jun; 38(3):201-4. PubMed ID: 16753739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
    Koperek O; Kornauth C; Capper D; Berghoff AS; Asari R; Niederle B; von Deimling A; Birner P; Preusser M
    Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
    Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
    Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
    Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
    Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas.
    Takano T; Ito Y; Hirokawa M; Yoshida H; Miyauchi A
    Br J Cancer; 2007 May; 96(10):1549-53. PubMed ID: 17453004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
    Wang Y; Ji M; Wang W; Miao Z; Hou P; Chen X; Xu F; Zhu G; Sun X; Li Y; Condouris S; Liu D; Yan S; Pan J; Xing M
    Endocr Relat Cancer; 2008 Mar; 15(1):183-90. PubMed ID: 18310286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
    Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
    Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
    Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy.
    Santoro A; Pannone G; Carosi MA; Francesconi A; Pescarmona E; Russo GM; Feola A; Losito S; Franco R; Nappi L; Aquino G; De Rosa G; Di Domenico M; Bufo P
    J Cell Biochem; 2013 May; 114(5):1174-82. PubMed ID: 23192464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
    Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
    Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.
    Erickson LA; Jin L; Nakamura N; Bridges AG; Markovic SN; Lloyd RV
    Cancer; 2007 May; 109(10):1965-71. PubMed ID: 17387744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.